comprehensive -WSS

comprehensive

author：hotspot 2025-10-02 11:07:36 - browse：75457

Neumora, a privately held biotech company, is moving into the final phase of testing with a novel treatment for depression that showed promise in a mid-stage trial.

The drug, a daily pill called navacaprant, led to statistically significant improvements over placebo on a measurement of disease severity for patients with moderate to severe major depressive disorder, Neumora said Tuesday. In the eight-week study, the medicine also led to improvements in patient-reported anhedonia, a reduced ability to experience pleasure that often accompanies severe depression.

Navacaprant’s statistically significant benefits came from a pre-specified subset of 100 patients in a study that enrolled 171 people. In the total population, including 71 patients who had mild to moderate disease, navacaprant’s effect on depressive symptoms was numerically superior to placebo but did not reach the threshold of statistical significance, missing the study’s primary endpoint.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Hawaii wildfires fueled by Hurricane Dora's winds prompt evacuations

WSS

Emergent cuts jobs, executive role in business shake

NIH confirmation hearing shows politicization of research

STAT Readout Newsletter: Today's biggest biotech updates

Eli Lilly expects to double planned employment in Boston center

CEOs share strategies for surviving biotech slump

For Cytokinetics, FDA rejection of heart drug would help, not hinder

hotspot

comprehensive

hotspot

Wildfire smoke exposes gaps in outdoor worker protections

Drastic changes should bring profitability, startup health insurers say

In age of alternative facts, a scholarly course on calling out crap

First Opinion Podcast: Long Covid needs a new approach

Novavax promises a turnaround & Lilly roils the obesity market

Eli Lilly expects to double planned employment in Boston center

Jerome Adams on the need for new antivirals for Covid

Lawmakers consider Medicare pay reforms for doctors

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

FDA warns J&J's Abiomed: We will regulate your software

Wikipedia

Emergent cuts jobs, executive role in business shake

Impact of Dobbs ruling felt at reproductive medicine meeting

Studies point to risks of excluding people with obesity from drug trials

Shkreli is convicted of fraud. Can pharma finally slam the door on him?

How climate

Friends ask where James Watson's attitudes about race came from

knowledge

knowledge

hotspot

hotspot